5-fluorouracil
ANXA2
ATC code L01
ATC code L04
ATC code S01
Abatacept
Abemaciclib
Abetimus
Acalabrutinib
Adagrasib
Adalimumab
Adipotide
Afatinib
Afelimomab
Aflibercept (data page)
Alectinib
Alefacept
Alemtuzumab
Alpelisib
American Society of Health-System Pharmacists
Amivantamab
Anakinra
Anaplastic lymphoma kinase
Anatomical Therapeutic Chemical Classification System
Anecortave
Anifrolumab
Anti-lymphocyte globulin
Anti-thymocyte globulin
Antibody
Antifolate
Antimetabolite
Antineoplastic
Antineovascularization agent
Apremilast
Asciminib
Aselizumab
Atezolizumab
Atezolizumab/hyaluronidase
Atorolimumab
Aumolertinib
Avacopan
Avapritinib
Avelumab
Aventis
Axatilimab
Axitinib
Azathioprine
BRAF (gene)
Baricitinib
Basigin
Basiliximab
Bcr-abl fusion protein
Begelomab
Belantamab mafodotin
Belatacept
Belimumab
Bermekimab
Bertilimumab
Bevacizumab
Bimekizumab
Binimetinib
Biosimilar
Blinatumomab
Blisibimod
Bosutinib
Brentuximab vedotin
Briakinumab
Brigatinib
Brodalumab
Brolucizumab
Bruton's tyrosine kinase
C-Met
CAS Registry Number
CD117
CD11a
CD135
CD154
CD18
CD20
CD23
CD30
CD33
CD3 (immunology)
CD4
CD40 (protein)
CD52
CD80
CDK inhibitor
CTLA-4
Cabozantinib
Calcineurin
Canakinumab
Cancer immunotherapy
Capillaries
Capmatinib
Catumaxomab
Cedelizumab
Cediranib
Cemiplimab
Centers for Medicare & Medicaid Services
Ceritinib
Certolizumab pegol
Cetuximab
ChEMBL
ChemSpider
Chemical formula
Chloramphenicol acetyltransferase
Choriocapillaris
Choroidal neovascularization
Ciclosporin
Clenoliximab
Clinical trial
Cobimetinib
Cochrane (organisation)
Colorectal cancer
Committee for Medicinal Products for Human Use
Complement component 5
Copanlisib
Cosibelimab
Crizotinib
Crovalimab
Cyclophilin
Dabrafenib
Daclizumab
Dacomitinib
DailyMed
Dalpiciclib
Danicopan
Daratumumab
Darvadstrocel
Dasatinib
Denileukin diftitox
Deucravacitinib
Deuruxolitinib
Diabetic retinopathy
Dihydroorotate dehydrogenase
Dimethyl fumarate
Dinutuximab beta
Diroximel fumarate
Doi (identifier)
Dostarlimab
DrugBank
Drug class
Drug nomenclature
Drugs.com
Durvalumab
Duvelisib
EML4
Eculizumab
Edrecolomab
Efalizumab
Efgartigimod alfa
Efgartigimod alfa/hyaluronidase
Elotuzumab
Elranatamab
Elsilimomab
Emapalumab
Encorafenib
End point of clinical trials
Enfortumab vedotin
Entrectinib
EpCAM
Epcoritamab
Epidermal growth factor receptor
ErbB
Erdafitinib
Erlizumab
Erlotinib
Etanercept
Etrasimod
European Medicines Agency
Everolimus
Exotoxin
FKBP
FOLFIRI
Faralimomab
Faricimab
Fedratinib
Fibroblast growth factor receptor
Filgotinib
Fingolimod
Floater
Fluorouracil
Folinic acid
Fontolizumab
Food and Drug Administration
Frexalimab
Fruquintinib
Fusion protein
Futibatinib
Galiximab
Gavilimomab
Gefitinib
Gemtuzumab ozogamicin
Gilteritinib
Glasdegib
Glofitamab
Golimumab
Gomiliximab
Guselkumab
Gusperimus
HCPCS
HER2/neu
Hedgehog signaling pathway
Hemorrhage
Hormone-refractory prostate cancer
Hypertension
IL-2 receptor
Ibritumomab tiuxetan
Ibrutinib
Icotinib
Idelalisib
Imatinib
Immunoglobulin
Immunoglobulin E
Immunomodulatory imide drug
Immunosuppression
Immunosuppressive drug
Inavolisib
Indicated
Inebilizumab
Infigratinib
Inflammation
Infliximab
Inolimomab
Inotuzumab ozogamicin
Integrin
Interferon
Interleukin
Interleukin-6 receptor
Interleukin 12
Interleukin 13
Interleukin 17
Interleukin 1 receptor antagonist
Interleukin 2
Interleukin 23
Interleukin 5
Interleukin 6
Intravenous
Intravenous therapy
Intravitreal
Intravitreal administration
Ipilimumab
Iptacopan
Irinotecan
Isatuximab
Itacitinib
Ixekizumab
Janus kinase
KEGG
KRAS
Keliximab
L-selectin
Lapatinib
Larotrectinib
Lazertinib
Lebrikizumab
Leflunomide
Lenalidomide
Lenvatinib
Lerdelimumab
Lestaurtinib
Leucovorin
Leukemia
Leukopenia
Loncastuximab tesirine
Lorlatinib
Lumiliximab
Lymphatic system
Lymphocyte function-associated antigen 1
Lymphoma
MEN1
MTOR
MTOR inhibitor
Macrolide
Masitinib
Maslimomab
Medicare (United States)
MedlinePlus
Mepolizumab
Metelimumab
Methotrexate
Midostaurin
Mirvetuximab soravtansine
Mitogen-activated protein kinase kinase
Mobocertinib
Mogamulizumab
Molar mass
Momelotinib
Monoclonal antibody
Monoclonal antibody therapy
Morolimumab
Mosunetuzumab
Moxetumomab pasudotox
Muromonab-CD3
Mycophenolic acid
Myeloid
Natalizumab
Naxitamab
Necitumumab
Neratinib
Nerelimomab
Netakimab
Neutropenia
Nilotinib
Nintedanib
Nivolumab
Non-receptor tyrosine kinase
Non-small cell lung cancer
Obinutuzumab
Ocrelizumab
Ocrelizumab/hyaluronidase
Ocular hypertension
Odronextamab
Odulimomab
Ofatumumab
Olaratumab
Olmutinib
Olokizumab
Omalizumab
Ophthalmology
Opinercept
Oportuzumab monatox
Orelabrutinib
Osimertinib
Otelixizumab
Oxaliplatin
Ozanimod
PDE4 inhibitor
PMC (identifier)
PMID (identifier)
Pacritinib
Palbociclib
Panitumumab
Parsaclisib
Pascolizumab
Pazopanib
Peficitinib
Pegaptanib
Pegcetacoplan
Pembrolizumab
Pemigatinib
Pertuzumab
Pexelizumab
Pexidartinib
Pi3K inhibitor
Pimecrolimus
Pirfenidone
Pirtobrutinib
Placental growth factor
Platelet-derived growth factor receptor
Polatuzumab vedotin
Polyclonal antibodies
Pomalidomide
Ponatinib
Ponesimod
Pralsetinib
Pregnancy category
Prescription drug
Proapoptotic
Prohibitin
Prolgolimab
Purine synthesis inhibitor
Quizartinib
RET proto-oncogene
RTK class III
Radotinib
Ramucirumab
Ranibizumab
Ravulizumab
Receptor (biochemistry)
Receptor tyrosine kinase
Recombinant DNA
Regeneron Pharmaceuticals
Regorafenib
Regulation of therapeutic goods
Repotrectinib
Reslizumab
Retifanlimab
Revumenib
Ribociclib
Ridaforolimus
Rilonacept
Ripretinib
Risankizumab
Ritlecitinib
Rituximab
Rociletinib
Route of administration
Rovelizumab
Rozanolixizumab
Ruplizumab
Ruxolitinib
Sabatolimab
Sacituzumab govitecan
Sarilumab
Satralizumab
Second-line treatment
Secukinumab
Selpercatinib
Selumetinib
Semaxanib
Serplulimab
Siltuximab
Siplizumab
Siponimod
Sirolimus
Sirukumab
Sonidegib
Sorafenib
Sotorasib
Spesolimab
Src (gene)
Standard for the Uniform Scheduling of Medicines and Poisons
Sugemalimab
Sunitinib
Sutimlimab
TNF inhibitor
T cell
Tacrolimus
Tafasitamab
Talizumab
Talquetamab
Targeted cancer therapy
Tarlatamab
Tebentafusp
Teclistamab
Telimomab aritox
Telitacicept
Temsirolimus
Teneliximab
Teplizumab
Tepotinib
Teprotumumab
Teriflunomide
Thalidomide
Thrombocytopenia
Tildrakizumab
Tislelizumab
Tisotumab vedotin
Tivozanib
Toceranib
Tocilizumab
Tofacitinib
Toralizumab
Toripalimab
Tositumomab
Trametinib
Trastuzumab
Trastuzumab/hyaluronidase
Trastuzumab deruxtecan
Trastuzumab emtansine
Tremelimumab
Trilaciclib
Tucatinib
Tyrosine kinase inhibitor
Ublituximab
Umirolimus
Unique Ingredient Identifier
Upadacitinib
Ustekinumab
VEGF-A
VEGF-B
VEGF receptors
Vandetanib
Vapaliximab
Vascular disorder
Vascular endothelial growth factor
Vascular endothelial growth factor A
Vedolizumab
Vemurafenib
Venetoclax
Vepalimomab
Verteporfin
Visilizumab
Vismodegib
Vitreous detachment
Voclosporin
Wet macular degeneration
Yahoo News
Zanidatamab
Zanolimumab
Zanubrutinib
Zenocutuzumab
Zolbetuximab
Zolimomab aritox
Zotarolimus